⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

EMCURE - Swing Trade Analysis with AI Signals

← Back to List

⭐ Rating: 3.2

Last Updated Time : 19 Sept 26, 04:05 am

Key Parameters

⭐ Swing Trade Rating: 3.2

RSI49.7
MACD14.2
DMA 501,886 ₹
DMA 2001,694 ₹
Volume1,41,786
Avg Vol 1Wk2,18,619
High / Low2,100 ₹
52w Index90.0 %
Show all parameters (20 more)
Stock CodeEMCURE
Market Cap38,241 Cr.
Current Price2,016 ₹
Stock P/E46.2
Book Value196 ₹
Dividend Yield0.19 %
ROCE23.7 %
ROE22.3 %
Face Value10.0 ₹
Chg in FII Hold1.52 %
Chg in DII Hold2.36 %
PAT Qtr200 Cr.
PAT Prev Qtr228 Cr.
Low price1,260 ₹
High price2,100 ₹
PEG Ratio0.70
Debt to equity0.43
Qtr Profit Var59.6 %
EPS42.7 ₹
Industry PE34.8

🧾 Trade Setup

Entry Price: 1,980 ₹ (anticipating a further upward movement based on momentum). Exit Guidance: Set a stop-loss order at 1,930 ₹ to mitigate downside risk while maintaining the position if the price reaches 2,150 ₹ – this represents a reasonable profit target given the current valuation. Verdict: This stock presents a moderate swing trading opportunity due to its strong recent performance and healthy financial metrics, but the premium valuation necessitates careful risk management.

✅ Positive

The stock is exhibiting strong near-term momentum, with a recent price gain and positive indicators like a robust ROE and healthy EPS growth. Furthermore, the RSI remains relatively low, suggesting potential for continued upside.

⚠️ Limitation

Despite impressive profitability, the high P/E ratio relative to the industry indicates significant premium valuation. This makes the stock vulnerable to corrections if market sentiment shifts or growth expectations are not fully met, particularly given that the stock trades at a higher P/E than its sector peers.

📈 Company Positive News

Emcure Pharmaceuticals has announced an ESOP allotment of 11,400 shares, which could positively impact investor confidence and potentially support share price appreciation if the company demonstrates continued success.

🏭 Industry

The pharmaceutical sector is currently experiencing moderate growth driven by increasing healthcare spending and generic drug demand. While competitive pressures exist, key players with strong product pipelines and established brands are generally well-positioned for near-term gains – Emcure benefits from this sector trend.

Choose Technical Analysis or Fundamental Analysis above to load it.

How EMCURE Rates Across All Strategies

Swing Trade
★ 3.2
You're viewing this analysis below.
★ 2.8
I’d recommend a buy at 2035 ₹ with an initial stop-loss order placed…
★ 3.2
An ideal entry price zone would be between 1,850 ₹ and 2,050 ₹, capit…
★ 3.2
Optimal entry zones would be between 1980-2025 ₹, utilizing the recen…
★ 3.2
An entry zone could be established around 1,850 ₹ – 1,920 ₹, taking i…

NIFTY 50 · Swing Trading

NEXT 50 · Swing Trading

MIDCAP · Swing Trading

SMALLCAP · Swing Trading